Our previous studies have indicated that lipid-based nanoparticles can trigger the secretion of gut hormone GLP-1 and that this effect can also be synergistic in the treatment of incretin-based diabetes via oral peptide therapy (17–19). Here, GLP1R is linked to diabetes mellitus.